SynthesisCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2020
Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis.
Synthesis in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 10 syntheses or guidelines pooled it, 101 citations in OpenAlex.
- Effect of convalescent plasma transfusion on outcomes of coronavirus disease 2019: a meta-analysis with trial sequential analysis.Journal of anesthesia · 2023Pooled it
- Hyperimmune immunoglobulin for people with COVID-19.The Cochrane database of systematic reviews · 2023Pooled it
- Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis.BMJ (Clinical research ed.) · 2021Pooled it
- Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.JMIR public health and surveillance · 2021Pooled it
- Convalescent plasma may be a possible treatment for COVID-19: A systematic review.International immunopharmacology · 2021Pooled it
- Convalescent plasma is a clutch at straws in COVID-19 management! A systematic review and meta-analysis.Journal of medical virology · 2021Pooled it
- Effect of convalescent blood products for patients with severe acute respiratory infections of viral etiology: A systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Pooled it
- Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis.F1000Research · 2021Pooled it
- Epidemiological and Clinical Characteristics of COVID-19 in Children: A Systematic Review and Meta-Analysis.Frontiers in pediatrics · 2020Pooled it
- COVID-19 Convalescent Plasma: from donation to treatment - A Systematic Review & Single Center Experience.Missouri medicinePooled it
- Should timing be considered before abandoning convalescent plasma in covid-19? Results from the Turkish experience.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2021Trial
- Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection.Nature communications · 2021Trial
- Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).BMJ (Clinical research ed.) · 2020Trial
- Therapeutic Potential of Neutralizing Monoclonal Antibodies (nMAbs) against SARS-CoV-2 Omicron Variant.Current pharmaceutical design · 2025Review
- COVID-19: Recent Insight in Genomic Feature, Pathogenesis, Immunological Biomarkers, Treatment Options and Clinical Updates on SARS-CoV-2.Current genomics · 2024Review
- Immunization technologies: Time to consider new preventative solutions for respiratory syncytial virus infections.Human vaccines & immunotherapeutics · 2023Article
- What are the current anti-COVID-19 drugs? From traditional to smart molecular mechanisms.Virology journal · 2023Review
- COVID-19 and Pregnancy: An Updated Review about Evidence-Based Therapeutic Strategies.Journal of personalized medicine · 2023Review
- Evaluation of Convalescent Plasma in the Management of Critically Ill COVID-19 Patients (with No Detectable Neutralizing Antibodies Nab) in Kashmir, India.Healthcare (Basel, Switzerland) · 2023Article
- Clinical nursing care protocol for convalescent plasma transfusion in patients with COVID-19.International journal of Africa nursing sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe safety and efficacy of convalescent plasma in severe coronavirus disease 2019 (COVID-19) remain uncertain. To support a guideline on COVID-19 management, we conducted a systematic review and meta-analysis of convalescent plasma in COVID-19 and other severe respiratory viral infections.
methodsIn March 2020, we searched international and Chinese biomedical literature databases, clinical trial registries and prepublication sources for randomized controlled trials (RCTs) and nonrandomized studies comparing patients receiving and not receiving convalescent plasma. We included patients with acute coronavirus, influenza and Ebola virus infections. We conducted a meta-analysis using random-effects models and assessed the quality of evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.
resultsOf 1099 unique records, 6 studies were eligible, and none of these included patients with COVID-19. One nonrandomized study (
interpretationStudies of non-COVID-19 severe respiratory viral infections provide indirect, very low-quality evidence that raises the possibility that convalescent plasma has minimal or no benefit in the treatment of COVID-19 and low-quality evidence that it does not cause serious adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.